Eikon Therapeutics, Inc. (EIKN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Eikon Therapeutics, Inc. (EIKN) closed at USD 7.01 on 2026-10-14, a change of -53.3 % over the past year, with a market capitalization of USD 408.4M.

Eikon Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Eikon Therapeutics, Inc. key figures

Previous close

USD 7.01 (2026-10-14)

1-year change

-53.3 %

Market cap

USD 408.4M

Enterprise value

USD 129.45M

P/E ratio (trailing)

-0.89

P/E ratio (forward)

-1.19

EPS (trailing)

-8.51

EPS (forward)

-6.33

PEG ratio

n/a

Price to book

0.88

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.76

Employees

384

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Eikon Therapeutics, Inc. and compare it with other stocks.